Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 1
1995 1
1996 1
2000 2
2001 3
2002 3
2003 3
2004 3
2006 5
2007 5
2008 1
2009 5
2010 6
2011 7
2012 6
2013 8
2014 6
2015 15
2016 12
2017 12
2018 7
2019 9
2020 8
2021 8
2022 11
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

PubMed for id: 1777703

146 results

Results by year

Filters applied: . Clear all
Page 1
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS.
Chaix J, Schleiermacher G, Corradini N, André N, Thebaud E, Gambart M, Defachelles AS, Entz-Werle N, Chastagner P, De Carli É, Ducassou S, Landman-Parker J, Adam-de-Beaumais T, Larive A, Michiels S, Vassal G, Valteau-Couanet D, Geoerger B, Berlanga P. Chaix J, et al. Eur J Cancer. 2024 Apr;201:113923. doi: 10.1016/j.ejca.2024.113923. Epub 2024 Feb 15. Eur J Cancer. 2024. PMID: 38377775
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.
Sholler GLS, Bergendahl G, Lewis EC, Kraveka J, Ferguson W, Nagulapally AB, Dykema K, Brown VI, Isakoff MS, Junewick J, Mitchell D, Rawwas J, Roberts W, Eslin D, Oesterheld J, Wada RK, Pastakia D, Harrod V, Ginn K, Saab R, Bielamowicz K, Glover J, Chang E, Hanna GK, Enriquez D, Izatt T, Halperin RF, Moore A, Byron SA, Hendricks WPD, Trent JM. Sholler GLS, et al. Genome Med. 2024 Feb 12;16(1):28. doi: 10.1186/s13073-024-01297-5. Genome Med. 2024. PMID: 38347552 Free PMC article. Clinical Trial.
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.
Hogarty MD, Ziegler DS, Franson A, Chi YY, Tsao-Wei D, Liu K, Vemu R, Gerner EW, Bruckheimer E, Shamirian A, Hasenauer B, Balis FM, Groshen S, Norris MD, Haber M, Park JR, Matthay KK, Marachelian A. Hogarty MD, et al. Br J Cancer. 2024 Mar;130(5):788-797. doi: 10.1038/s41416-023-02525-2. Epub 2024 Jan 10. Br J Cancer. 2024. PMID: 38200233 Free PMC article. Clinical Trial.
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, Amador CM, Ghatwai N, Rathi P, Wood MS, Li Y, Zhang C, Demberg T, Di Pierro EJ, Sher AC, Zhang H, Mehta B, Thakkar SG, Grilley B, Wang T, Weiss BD, Montalbano A, Subramaniam M, Xu C, Sachar C, Wells DK, Dotti G, Metelitsa LS. Heczey A, et al. Nat Med. 2023 Jun;29(6):1379-1388. doi: 10.1038/s41591-023-02363-y. Epub 2023 May 15. Nat Med. 2023. PMID: 37188782 Clinical Trial.
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Berko ER, Witek GM, Matkar S, Petrova ZO, Wu MA, Smith CM, Daniels A, Kalna J, Kennedy A, Gostuski I, Casey C, Krytska K, Gerelus M, Pavlick D, Ghazarian S, Park JR, Marachelian A, Maris JM, Goldsmith KC, Radhakrishnan R, Lemmon MA, Mossé YP. Berko ER, et al. Nat Commun. 2023 May 5;14(1):2601. doi: 10.1038/s41467-023-38195-0. Nat Commun. 2023. PMID: 37147298 Free PMC article.
146 results